Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks by Ruhl, Louisa et al.








Endothelial dysfunction contributes to severe COVID-19 in combination
with dysregulated lymphocyte responses and cytokine networks
Ruhl, Louisa ; Pink, Isabell ; Kühne, Jenny F ; Beushausen, Kerstin ; Keil, Jana ; Christoph, Stella ;
Sauer, Andrea ; Boblitz, Lennart ; Schmidt, Julius ; David, Sascha ; Jäck, Hans-Martin ; Roth, Edith ;
Cornberg, Markus ; Schulz, Thomas F ; Welte, Tobias ; Höper, Marius M ; Falk, Christine S
Abstract: The systemic processes involved in the manifestation of life-threatening COVID-19 and in
disease recovery are still incompletely understood, despite investigations focusing on the dysregulation of
immune responses after SARS-CoV-2 infection. To define hallmarks of severe COVID-19 in acute disease
(n = 58) and in disease recovery in convalescent patients (n = 28) from Hannover Medical School, we used
flow cytometry and proteomics data with unsupervised clustering analyses. In our observational study,
we combined analyses of immune cells and cytokine/chemokine networks with endothelial activation and
injury. ICU patients displayed an altered immune signature with prolonged lymphopenia but the expan-
sion of granulocytes and plasmablasts along with activated and terminally differentiated T and NK cells
and high levels of SARS-CoV-2-specific antibodies. The core signature of seven plasma proteins revealed
a highly inflammatory microenvironment in addition to endothelial injury in severe COVID-19. Changes
within this signature were associated with either disease progression or recovery. In summary, our data
suggest that besides a strong inflammatory response, severe COVID-19 is driven by endothelial activation
and barrier disruption, whereby recovery depends on the regeneration of the endothelial integrity.
DOI: https://doi.org/10.1038/s41392-021-00819-6






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Ruhl, Louisa; Pink, Isabell; Kühne, Jenny F; Beushausen, Kerstin; Keil, Jana; Christoph, Stella; Sauer,
Andrea; Boblitz, Lennart; Schmidt, Julius; David, Sascha; Jäck, Hans-Martin; Roth, Edith; Cornberg,
Markus; Schulz, Thomas F; Welte, Tobias; Höper, Marius M; Falk, Christine S (2021). Endothelial
dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses
and cytokine networks. Signal Transduction and Targeted Therapy, 6:418.
DOI: https://doi.org/10.1038/s41392-021-00819-6
ARTICLE OPEN
Endothelial dysfunction contributes to severe COVID-19 in
combination with dysregulated lymphocyte responses and
cytokine networks
Louisa Ruhl1, Isabell Pink2, Jenny F. Kühne1, Kerstin Beushausen1, Jana Keil1, Stella Christoph1, Andrea Sauer2, Lennart Boblitz2,
Julius Schmidt2, Sascha David3, Hans-Martin Jäck4, Edith Roth4, Markus Cornberg5,6, Thomas F. Schulz7,8,9, Tobias Welte2,10,
Marius M. Höper2,10 and Christine S. Falk 1,8,10✉
The systemic processes involved in the manifestation of life-threatening COVID-19 and in disease recovery are still incompletely
understood, despite investigations focusing on the dysregulation of immune responses after SARS-CoV-2 infection. To define
hallmarks of severe COVID-19 in acute disease (n= 58) and in disease recovery in convalescent patients (n= 28) from Hannover
Medical School, we used flow cytometry and proteomics data with unsupervised clustering analyses. In our observational study, we
combined analyses of immune cells and cytokine/chemokine networks with endothelial activation and injury. ICU patients
displayed an altered immune signature with prolonged lymphopenia but the expansion of granulocytes and plasmablasts along
with activated and terminally differentiated T and NK cells and high levels of SARS-CoV-2-specific antibodies. The core signature of
seven plasma proteins revealed a highly inflammatory microenvironment in addition to endothelial injury in severe COVID-19.
Changes within this signature were associated with either disease progression or recovery. In summary, our data suggest that
besides a strong inflammatory response, severe COVID-19 is driven by endothelial activation and barrier disruption, whereby
recovery depends on the regeneration of the endothelial integrity.
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INTRODUCTION
In December 2019, first cases of patients suffering from severe
acute respiratory syndrome (SARS) were observed following
infection with the severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2). The new coronavirus rapidly spread around the
globe and was declared as a pandemic by the World Health
Organization (WHO) on March 11, 2020.1 The associated corona-
virus disease 2019 (COVID-19) ranges from an asymptomatic state
or mild symptoms to severe progression and lethal outcome.2 As of
May 2021 SARS-CoV-2 infected more than 150,000,000 people
worldwide and caused more than 3,200,000 deaths.
The upper respiratory tract and the lung are the primary sites of
SARS-CoV-2 infection and dyspnea is a leading symptom of severe
COVID-19 with respiratory failure causing admission to intensive
care unit (ICU) and mechanical ventilation.3 Pulmonary symptoms
are mainly caused by infection of epithelial cells, particularly type II
alveolar epithelial cells, via angiotensin-converting enzyme 2
(ACE2) as a receptor for the SARS-CoV-2 spike protein following
proteolytic cleavage by the TMPRSS2 protease, facilitating viral
entry.4 Sustained uncontrolled infection results in extensive death
of barrier cells within the alveoli and leads to vascular leakage
along with tissue edema and activation of coagulation pathways.5
These processes ultimately promote the formation of an acute
respiratory distress syndrome (ARDS), a major clinical feature of
severe COVID-19. Pulmonary complications resulting from
endothelial damage can be caused by multiple mechanisms in
the case of SARS-CoV-2. Next to infection of endothelial cells by the
virus, also decreased activity of ACE2 due to binding of SAS-CoV-2
inducing the kallikrein-bradykinin pathway, can lead to increased
barrier breach.5 Furthermore, reactive oxygen species produced by
activated neutrophils can damage barrier cells and immune cells in
addition to inflammatory plasma proteins, which promote
endothelial disruption.5 In severe cases, patients can also develop
further endothelium-associated complications like heart diseases,
abnormal blood coagulation, and neurological complications as
well as liver and kidney injuries, which can progress to multiorgan
failure.6 These clinical symptoms indicate crucial participation of
the endothelial system in the manifestation of severe COVID-19.
The reasons for the wide range of COVID-19 symptoms and
variable, unpredictable disease progressions are under intense
investigation. Age and age-related chronic inflammatory conditions
such as diabetes together with genetic predispositions represent
major risk factors for severe COVID-19.7 Furthermore, several studies
suggested a direct connection between the host immune response
and critical COVID-19, demonstrating dynamic and highly hetero-
geneous immune signatures with altered immune cell compositions
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and cytokine/chemokine patterns in severe COVID-19.8–10 SARS-
CoV-2 seems to manipulate the host immunity by evading especially
the innate immune response, as ineffective IFN immunity was
associated with fatal COVID-19.7,11 Besides the innate, also the
adaptive immunity contributes to progression toward severe
COVID-19.11 In particular, SARS-CoV-2-specific T cells are crucial for
rapid virus clearance since an extended absence of virus-specific
T cells was related to severe COVID-19 progression.12 Regarding the
humoral response, >90% of infected individuals seroconverted to
SARS-CoV-2 spike (S) and/or nucleocapsid (N) proteins, but rather
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limited somatic hypermutation was observed for neutralizing
antibodies,9,13 indicating also an altered B-cell response. Addition-
ally, cytokine profiles from severe SARS-CoV-2 infections revealed a
highly inflammatory microenvironment with elevated levels of
cytokines like IL-6 and TNF-α and chemokines like CXCL-10 in
addition to altered antiviral IFN responses.7,8,10
As clinical symptoms indicate a crucial endothelial contribution
to severe COVID-19 our study aimed to investigate a potential link
between the endothelium and hyperinflammation in critical cases.
We focused on identifying immune and endothelial signatures as
main drivers for severe COVID-19 progression since uncovering
pathological mechanisms may be a first step for developing novel
treatment strategies and could help to understand long-lasting
effects in recovered patients.14 Therefore, we included blood
samples from acute severe COVID-19 patients admitted to
intensive care unit (ICU, n= 58) and from convalescent, former
ICU patients (CONV, n= 28) in our study. Cellular, humoral, and
endothelial responses were analyzed, and patterns were identified
by unsupervised clustering and correlation matrices. First, we
observed a dominating hyperactivated HLA-DR+/CD38+ pheno-
type of memory T and NK cells despite massive T-cell lymphopenia.
Second, granulocytes were significantly expanded as well as
plasmablasts, which were accompanied by a rapid production of S-
and N-specific IgM, IgA, and IgG antibodies. Third, in severe COVID-
19, this hyperactivation at the cellular level was accompanied by a
highly pro-inflammatory cytokine/chemokine network, which was
associated with endothelial activation leading to a stepwise
disruption of the endothelial barrier. Finally, unsupervised cluster
and correlation analyses identified a unique core chemokine/
endothelial signature for severe COVID-19 as well as distinct
cytokine signatures associated with recovery from severe disease.
RESULTS
Dynamic changes in the entire immune cell composition in severe
COVID-19 patients with memory T-cell development and
plasmablast expansion
A total of N= 42 patients with n= 86 samples from MHH with
confirmed SARS-CoV-2 infection were analyzed at various time
points after symptom onset. N= 25 patients (n= 58 samples)
have been admitted to ICU and N= 17 patients (n= 28 samples)
were convalescent former ICU patients (CONV). N= 29 unexposed
individuals (UE, n= 29 samples) served as control group (S1,
Supplementary Table 1). To analyze the leukocyte dynamics
during COVID-19, we quantified their absolute numbers and
proportions in ICU, CONV, and UE. Unsupervised cluster analyses
of our immune phenotyping datasets (Supplementary Fig. S2)
revealed a clear separation of ICU from CONV and UE, indicating
significant dynamic changes in the lymphocyte compartment
during acute COVID-19 (Fig. 1a, b and Supplementary Fig. S3a). As
known from other studies,8,15 both absolute numbers as well as
frequencies of granulocytes were highly elevated in blood of ICU
patients while monocytes were stable and only proportionally
reduced (Fig. 1c and Supplementary Fig. S3b). In contrast, absolute
numbers as well as frequencies of lymphocytes, especially T cells,
were significantly decreased in ICU compared to CONV and UE,
with some patients showing strong lymphopenia (<1000 lympho-
cytes/µl blood). The number of NK cells was also decreased,
whereas B-cell numbers were unchanged in ICU compared to
CONV and UE. Leukocyte numbers and frequencies of CONV
displayed no significant differences compared to UE (Fig. 1c and
Supplementary Fig. S3b). Interestingly, four out of five deceased
ICU patients clustered close to each other and exhibited
decreased numbers of T cells and an activated immune
phenotype (Fig. 1b and Supplementary Fig. S3a). As reported
earlier, ICU patients show a strong decline in lymphocyte
numbers, including T and NK cells, leading to lymphopenia along
with an unusual expansion of granulocytes. Furthermore, compar-
able leukocyte numbers and frequencies of CONV and UE indicate
recovery at the cellular level in the periphery of CONV.
To further investigate the T-cell phenotypes in severe COVID-19,
the distribution of naive vs. memory CD4+ and CD8+ T cells was
determined for ICU, CONV, and UE based on the expression of the
chemokine receptor CCR7 and the CD45RO memory marker
(Supplementary Fig. S2a). Especially ICU showed highly variable
numbers and proportions of all T-cell subsets (Fig. 1d, e and
Supplementary Fig. S3c, d). CD8+ T-cell numbers, particularly
CCR7+CD45RO− naive and CCR7+CD45RO+ central memory (CM)
T cells were decreased in ICU compared to CONV and UE (Fig. 1d). In
addition, all CD4+ T cells subsets were significantly reduced in
numbers (Fig. 1e). With regards to CONV, we found elevated
numbers of CD8+ T cells compared to UE, especially CCR7−CD45RO+
effector memory (EM) and CCR7−CD45RO− TEMRA at the cost of
naive CD8+ T cells, which translated into a reduced CD4+/CD8+ ratio
compared to UE and ICU (Fig. 1d). Thus, CD4+ and CD8+ T cells were
both affected by the lymphopenia in COVID-19 ICU patients, and
particularly elevated CD8+ TEMRA T-cell numbers in CONV suggest a
pronounced T-cell differentiation during SARS-CoV-2 infection.
In contrast to T cells, B cells were less affected by lymphopenia
in ICU (Fig. 1c). Detailed analyses of B-cell subsets showed a broad
range of IgD+CD27− naive, CD27+IgD− memory (mem),
CD27+IgD+ switch precursor (switch pre), and IgD−CD27– effector
memory (eff-mem) B cells in ICU accompanied by an unusual
expansion of CD19+CD20−CD27+CD38+ plasmablasts (Fig. 1f and
Supplementary Figs. S2c, S3e). Even though we did not observe
significant differences in absolute numbers of these B-cell subsets
in ICU, frequencies of naive B cells were increased and frequencies
of eff-mem B cells were decreased in CONV compared to UE and
ICU (Fig. 1f and Supplementary Fig. S3e). Concluding, elevated
absolute numbers and proportions of plasmablasts in ICU patients
indicate a strong systemic B-cell response during acute SARS-CoV-
2 infection followed by a reverse transformation of the B-cell
population in CONV with elevated proportions of naive B cells and
reduced proportions of eff-mem B cells.
Plasmablasts contribute to antibody development and blocking
activity is associated with disease severity
Based on the massive plasmablast expansion in ICU, we
hypothesized that their presence in circulation might
be accompanied by the appearance of SARS-CoV-2-specific
Fig. 1 Dynamic changes in the entire immune cell composition in severe COVID-19 patients with memory T-cell development and
plasmablast expansion. Immune cell distribution reflected by absolute numbers in patient blood was analyzed using TruCount analyses. a, b
Multigroup comparison with a P value cutoff of 0.041 was used to identify significant differences among UE (n= 29), ICU (n= 58) and CONV
(n= 28) for (a) principal component analysis and (b) heatmap analysis. Blue to yellow scale represents the expression values normalized to
mean= 0, var= 1. Missing values are displayed in white. c–f Numbers of different immune cells in patient blood. T cells: naive (CCR7 +
CD45RO−), central memory (CM, CCR7+ CD45RO+ ), effector memory (EM, CCR7−CD45RO + ) and TEMRA (CCR7−CD45RO−); B cells: naive
(IgD + CD27−) memory (mem, CD27 + IgD−), switch precursor (switch pre, CD27 + IgD + ), effector memory (eff mem, IgD−CD27−) and
plasmablasts (CD19 + CD20−CD27 + CD38 + ). Black triangles represent last samples from deceased patients. UE: unexposed donors, ICU:
intensive care unit patients, CONV: convalescent patients, CM: central memory, EM: effector memory, mem eff: memory effector, switch pre:
switch precursor. Statistical analysis: ANOVA test with Turkey multiple comparison test or Kruskal–Wallis with test with Dunn’s multiple
comparison test were performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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antibodies. A Luminex-based multiplex assay was used to detect
IgM, IgA, and IgG specific for the S1, the receptor-binding domain
(RBD), and the S2 regions of the spike protein (S) and the
nucleocapsid (N) antigen of SARS-CoV-2 in plasma of ICU and
CONV, while UE served as controls. In ICU, high IgG relative
concentrations (MFI) were detected against all four SARS-CoV-2
antigens with the exception of two B-cell-depleted patients, while
IgM and IgA displayed broad variations of 45–100% positive
samples (Fig. 2a–c). In contrast, CONV showed decreased
proportions of seroconversion and lower concentrations of IgM
and IgA (Fig. 2a–d). Since the ICU samples were obtained during
acute infection, they were collected earlier in the course of
disease than CONV samples, which was reflected by the different
IgM, IgA, and IgG kinetics and, thus, illustrated a time-dependent
antibody-class switch from IgM to IgG and IgA (Supplementary
Fig. S4a, b). The decline of IgM and IgA levels 20 days after
Endothelial dysfunction contributes to severe COVID-19 in combination. . .
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Fig. 2 Plasmablasts contribute to antibody development and blocking activity is associated with disease severity. a–e Luminex-based
multiplex assay was used to detect IgM, IgA, and IgG antibodies against S1-, RBD, S2-, or N-antigen of SARS-CoV-2 in patient sera. a–c
Percentage of seroconverted ICU (n= 58) and CONV (n= 28) patients for SARS-CoV-2-specific IgM (a), IgA (b), and IgG (c) antibodies. The
threshold for positive samples was calculated based on the mean fluorescent intensity (MFI) of antibodies from 36 UEs + 2× standard
deviation. d Antibody levels from UE (n= 36), ICU (n= 58), and CONV (n= 28) are displayed as MFI. e Correlation analysis between S- and
N-specific antibodies from ICU patients and plasmablasts proportions. f Percentage of ICU (n= 58) and CONV (n= 28) which developed
blocking antibodies against SARS-CoV-2 RBD (left) and efficacy of blocking activity (right), which was assessed by competitive ELISA. Efficient
blocking was expressed as the percent blocking at a 1:50 serum dilution relative to a UE serum control. g Correlation analysis between COVID-
19 severity markers (CRP levels, SOFA-, WHO score, and PF ratio) and blocking efficiency from ICU patients. Black triangles represent last
samples from deceased patients. Statistical analysis: multigroup comparisons were performed using ANOVA test with Turkey multiple
comparison test or Kruskal–Wallis with test with Dunn’s multiple comparison test. Two-group comparison was performed using
Mann–Whitney test; Spearman correlation. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
Fig. 3 Expansion of activated and terminally differentiated T and NK cells in COVID-19 ICU patients. a Volcano plot visualizing two-group
comparison of flow cytometry data including proportions of immune cells from ICU (n= 58) and UE (n= 29). b Significantly (P ≥ 0.05) altered
immune cell subsets between ICU (n= 58) and UE (n= 29) ordered based on their fold change. c, d Representative flow cytometry plots. e, f
Representative flow cytometry data of immune cell frequencies from UE (n= 29), ICU (n= 58) and CONV (n= 28). Statistical analysis:
multigroup comparison was performed using ANOVA test with Turkey multiple comparison test or Kruskal–Wallis with test with Dunn’s
multiple comparison test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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symptom onset (DASO) in ICU was accompanied by increased IgG
levels that remained high up to 200 days after symptom onset in
CONV (Supplementary Fig. S4a, b). No major differences in IgM,
IgA, and IgG responses were detected between the S- and
N-antigens arguing for humoral responses against multiple
SARS-CoV-2 antigens (Fig. 2d).
To unravel a potential relationship between plasmablast expansion
and the occurrence of S- or N-specific antibodies, we correlated the
proportions of plasmablasts with the corresponding relative antibody
levels. While no correlation was found between plasmablasts and IgM
antibodies, there was a weak positive correlation between plasma-
blasts and S- and N-specific IgA and IgG (Fig. 2e). Moreover, a
Endothelial dysfunction contributes to severe COVID-19 in combination. . .
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competitive ELISA was performed to analyze whether antibodies in
ICU were able to block in vitro binding of SARS-CoV-2 RBD (wildtype)
to the ACE2 receptor. Interference was calculated as percent blocking
in the presence of ICU plasma (1:50 dilution) relative to UE control
plasma without SARS-CoV-2 antibodies. Interestingly, 85% of ICU and
75% CONV plasma samples contained interfering antibodies (Fig. 2f),
but the blocking efficacy of ICU antibodies was significantly higher
(median 40%) than CONV antibodies (median 24%) (Fig. 2f). Especially
deceased patients exhibited high blocking activity (>60%) except for
one B-cell-depleted patient. Moreover, we correlated antibody-
blocking efficacy with disease severity makers: C-reactive protein
(CRP) level as a marker for systemic inflammation, sepsis-related
organ failure assessment (SOFA) score for the extent of systemic
organ failure, World Health Organizations (WHO) eight-point scale for
COVID-19 trial endpoints (https://www.who.int/publications/i/item/
covid-19-therapeutic-trial-synopsis) and PaO2/FiO2 (PF) ratio repre-
senting the pulmonary function. CRP levels, SOFA- and WHO scores
showed weak positive correlations with the antibody-blocking
efficacy in ICU, whereas PF ratios were negatively correlated.
Interestingly, deceased patients displayed remarkably high CRP levels,
SOFA-, and WHO scores and low PF ratios (Fig. 2g).
These results illustrate that the majority of ICU developed rapid
and sustained IgG antibody responses specific for SARS-CoV-2 S-
and N-proteins and their blocking efficacy seemed to increase
with disease severity suggesting that antibodies were insufficient
to protect from developing severe COVID-19.
Expansion of activated and terminally differentiated T and NK cells
in COVID-19 ICU patients
Next, we aimed to identify the major immune cell populations
significantly altered in ICU versus UE to determine ICU-associated
cellular patterns. Unbiased volcano plot analysis depicted a strong
decline in lymphocytes but high frequencies of HLA-DR+CD38+
activated CD4+ and CD8+ T cells together with HLA-DR+ NK cells
and CD57+ terminally differentiated T and NK cells in ICU
compared to UE (Fig. 3a, b). These high frequencies of activated
HLA-DR+CD38+ T cells (Fig. 3c) together with HLA-DR+ and CD69+
activated CD56dim NK cells (Fig. 3d) were associated with acute
COVID-19 and decreased with recovery in CONV (Fig. 3e, f).
Proportions of CD28−CD27− or CD57+CCR7− terminally differ-
entiated T and CD57+ NK cells were increased in ICU and
remained elevated in CONV compared to UE (Fig. 3f). Conse-
quently, CD127+CD8+ T-cell frequencies were decreased in ICU as
well as in CONV compared to UE. Thus, severe SARS-CoV-2
infection is associated with strong activation and differentiation
into late memory T and NK cells.
In severe COVID-19, lymphocyte dynamics correlate with disease
progression
In order to examine the implications of the significant changes
within the lymphocyte compartment in ICU, they were correlated
to disease severity (SOFA-, WHO scores, CRP level) and progression
(days after symptom onset, DASO). Several immune cell subsets
significantly correlated with DASO, for example, plasmablasts with
a negative correlation, showing that plasmablasts developed early
during severe disease but decreased with prolonged ICU
hospitalization (Fig. 4a, b). In the myeloid compartment, propor-
tions of CD14+CD16+ intermediate and CD14−CD16+ non-
classical monocytes showed a positive correlation to DASO. In
parallel, NK cells increased with a simultaneous reduction of
activated CD69+ or CD25+ NK cells over time (Fig. 4c, d).
Moreover, different T-cell subsets correlated with disease duration,
indicating a time-dependent T-cell differentiation caused by
severe COVID-19 (Fig. 4e). While naive CD8+, CD4+ T, and
CD25hiCD127lo Treg cells decreased after symptom onset, EM as
well as HLA-DR+CD38+ activated CD8+ T cells accumulated over
time (Fig. 4e, f). As expected, frequencies of naive CD8+ T cells
negatively and EM CD8+ T cells positively correlated with patient
age in ICU (Supplementary Fig. S5a, b). However, since no
correlation was observed between COVID-19 disease duration and
patient age, we conclude that age had a minor impact on T-cell
differentiation during severe COVID-19 (Supplementary Fig. S5c).
Remarkably, CD4+ T cells and CD8+ TEMRA T cells did not follow
the usual age correlation in ICU compared to UE (Supplementary
Fig. S5a, b).
Unlike disease progression, severity markers (SOFA-, WHO-score,
CRP level) correlated with only a few immune cell subsets,
suggesting that disease severity had only a minor effect on the
immune cell distribution (Supplementary Fig. S6a). As expected,
especially activated immune cells like CD69+CD8+ T cells and
CD69+CD56bright NK cells positively correlated with CRP levels.
Furthermore, t-distributed stochastic neighbor embedding
(tSNE) (Fig. 4g) and unsupervised cluster analyses (Fig. 4h)
revealed two distinct subgroups of ICU samples, which separated
based on their DASO into a “late” and “early” subgroup (Fig. 4h
and Supplementary Fig. S6b, S6c). The “late” ICU subgroup
consisted of samples obtained between day 7 to 68 (mean
34 days), whereas the “early” ICU subgroup consisted of samples
from day 4 to 29 after symptom onset (mean 15 days). The two
groups did not display significant differences regarding their
SOFA- and WHO scores or PF ratios but the late subgroup
exhibited decreased CRP levels compared to the early subgroup
(Supplementary Fig. S6d). However, detailed analyses of the
immune cell compositions illustrated that these two subgroups
could additionally be distinguished by several immune cell
proportions (Fig. 4h–j). Particularly expression of the activation
markers HLA-DR, CD38, and CD25 and frequencies of CD45RO+ or
CD57+ memory T and NK cells increased with disease duration in
ICU, whereas consequently, proportions of naive T and NK cells
declined over time (Fig. 4h–j).
These results show that the alterations within the lymphocyte
compartment are strongly time-dependent during the individual
ICU period but are less directly associated with disease severity.
Systemic inflammation and endothelial injury in COVID-19
patients
With regards to the systemic microenvironment, we quantified
concentrations of 83 plasma proteins in ICU, CONV, and UE
Fig. 4 In severe COVID-19, lymphocyte dynamics correlate with disease progression. a, c, e Waterfall-plot representing correlation coefficient
(r) of Spearman-correlation analysis between immune cell proportions of B cells, monocytes, lymphocytes, and granulocytes (a) or NK cells (c),
or T cells (e) and disease duration as days after symptom onset (DASO) from ICUs (n= 58). Red columns represent significant results. Dotted
lines represent the minimal Spearman-correlation coefficient (r) required for significant correlation. b, d, f Spearman-correlation analysis
between proportions of plasmablasts (b), NK cells (d), or different T-cell populations (f) and DASO from ICUs (n= 58). G tSNE analysis of flow
cytometry data from ICU (n= 58). A variance-value cutoff of 0.305 was used to identify significant differences within the ICU cohort. Patients
were classified into two groups. Blue: late subgroup (n= 32), yellow: early subgroup (n= 26). h Heatmap of flow cytometry data including 98
immune cell populations from ICU (n= 58). A variance-value cutoff of 0.035 was used to identify significant differences within the ICU cohort.
Samples and immune cell subsets were ordered according to hierarchical clustering. Blue to yellow scale represents the expression values
normalized to mean=0, var=1. Missing values are displayed in white. i, j Representative immune cell proportions from early (n= 26) and late
patients (n= 32) within the ICU cohort. Statistical analysis: Unpaired t test or Mann–Whitney test; Spearman correlation. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001
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including cytokines, chemokines, growth factors, and endothelial
factors. Samples from ICU clearly clustered separately from CONV
and UE and displayed significantly increased levels of 65 plasma
proteins (Fig. 5a). Deceased ICU patients clustered in separated
patterns, indicating different plasma protein signatures associated
with fatal outcome. To identify the most statistically significant
plasma proteins discriminating ICU from UE, we analyzed their
levels based on the fold change between ICU and UE (Fig. 5b). The
volcano plot illustrates a COVID-19-associated plasma protein
profile composed of pro-inflammatory cytokines and chemokines
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(e.g., IL-6, CXCL10) in addition to growth factors (e.g.,
granulocyte–macrophage colony-stimulating factor (GM-CSF))
and endothelial factors (e.g., osteopontin (OPN), angiopoietin-2
(Ang-2)). In particular, chemokines and endothelial activation
markers correlated with each other in clusters (Fig. 5c), indicating
a co-regulated secretion and suggesting that inflammation and
endothelial injury may collectively contribute to severe COVID-19.
Furthermore, we observed high variability in the respective
plasma proteins levels within the ICU cohort, as previously
observed for immune cell populations (Fig. 5d and Supplementary
Fig. S7). In addition to classical inflammation-associated cytokines
(e.g., IL-1β, IL-6, TNF-α, IFN-γ) ICU displayed increased levels of
soluble interleukin-6 receptor α (sIL-6Rα), urokinase-type-
plasminogen activator (uPA), and its antagonist plasminogen-
activator inhibitor 1 (PAI-1) (Fig. 5d and Supplementary Fig. S7).
Whereas Ang-2, a central mediator of endothelial activation, was
elevated, the concentrations of its soluble angiopoietin receptor 2
(sTIE-2) were stable in ICU, CONV, and UE, suggesting regulation at
the ligand and not the receptor level. Endothelial activation
in ICU was further detectable by significantly higher insulin-like
growth factor-binding protein 1 (IGFBP-1), OPN, and vascular cell
adhesion protein 1 (VCAM-1) levels, accompanied by several
others. Organ contribution could be seen by higher hepatocyte
growth factor (HGF) levels, for instance (Fig. 5d). Of note, the
plasma protein profile of CONV displayed no significant alterations
compared to UE.
In summary, we observed a highly inflammatory profile of
plasma proteins in ICU, indicating strong immune system
activation due to SARS-CoV-2 infection. Furthermore, high levels
of endothelial factors suggest that endothelial injury may be a
crucial contributor to severe COVID-19 progression.
Core plasma protein signature of severe COVID-19 consists of
eleven inflammatory mediators and endothelial factors
Based on the extensive secretion of immunomodulating proteins
and endothelial factors in ICU, we aimed to examine their
implications for disease severity (SOFA-, WHO scores, and CRP
levels) and disease duration (DASO). Several plasma protein
levels positively correlated with disease duration such as IL-13,
IL-1β, GM-CSF, and the vascular endothelial growth factor (VEGF)
showing an extraordinary increase beyond day 20 after symptom
onset (Fig. 6a, b). In contrast, CXCL10 and IL-12(p40) concentra-
tions significantly decreased over time. Deceased ICU patients
displayed particularly low IL-1β and IL-13 levels, while CXCL10
and IL-12(p40) plasma concentrations were increased (Fig. 6b).
High SOFA scores correlated with high levels of chemokines like
CXCL10 and endothelial factors like HGF, IGFBP-1, and uPA
(Fig. 6c, d). Based on the highly inflammatory profiles of these
ICU patients, it was not surprising that correlation analyses with
CRP levels and WHO scores showed almost identical patterns
(data not shown). Comparing plasma proteins positively corre-
lated with either CRP levels, SOFA- or WHO scores, we detected
an intersection of seven shared plasma proteins, representing
the core signature associated with severe COVID-19 (Fig. 6e). This
signature was composed of the pro-inflammatory cytokines IL-12
(p40) and IL-6, the growth factor stem cell growth factor beta
(SCGF-β), the chemokines CXCL8-10, and the endothelial factor
HGF. Furthermore, IGFBP-1, IL-16, macrophage colony-
stimulating factor (M-CSF), and VCAM-1 positively correlated
with SOFA- and WHO scores, representing the contribution of
the endothelium to severe COVID-19. Additional plasma proteins
as IL-17F, IL-25, and CCL2 contributed to the unique WHO
pattern, while IL-31, CCL27, CCL7, uPA, and sCD25 were included
in the unique SOFA score-associated pattern and CXCL1
completed the CRP pattern.
Taken together, these signatures demonstrate that severe
COVID-19 is characterized by extensive secretion of multifunc-
tional interleukins, growth factors, and endothelial factors into the
circulation, suggesting that SARS-CoV-2 causes more than a
systemic inflammation but multiple endothelial injuries.
Endothelial dysregulation as a major contributor to severe
COVID-19
Finally, since we observed distinct plasma protein patterns in
deceased ICU patients (Fig. 5a), we wanted to assess whether
severe COVID-19 progression could be associated with distinct
profiles of ICU patients. Unsupervised tSNE analysis of plasma
proteins revealed three different subgroups within the ICU
cohort (Fig. 7a) that clearly clustered separately, with the
highest cytokine concentrations in subgroup 3 (Sub3) followed
by subgroup 2 (Sub2) and subgroup 1 (Sub1) (Fig. 7b).
Furthermore, Sub1-3 differed by their disease severity (SOFA-,
WHO scores, CRP levels, PF ratio) and disease progression
(DASO) (Fig. 7c, d). Of note, Sub2 contained ICU patients (n=
16) with the lowest CRP levels, SOFA- and WHO scores but
highest PF ratios and with the longest disease durations
(DASO) plus one deceased patient with chronic renal failure
after renal transplantation (Fig. 7c, d). On the contrary, Sub3
(n= 28) displayed the highest SOFA- and WHO scores among
the three subgroups containing two deceased patients. The
lowest PF ratios and highest CRP levels were observed for Sub1
(n= 14) with two deceased patients. The plasma protein
profiles demonstrated clear differences among these three
ICU subgroups (Fig. 7e). In general, the lowest cytokine levels
were observed for Sub1, which nevertheless still displayed
significantly higher levels of key cytokines and chemokines like
IL-6, IFN-γ, and CXCL10 compared to UE (Supplementary Fig.
S8). Sub3 exhibited the strongest inflammatory signature with
high levels of pro-inflammatory cytokines like IL-6, IL-18, and
TNF-α in addition to sIL-6Rα and the chemokines CXCL8-10
(Fig. 7d and Supplementary Fig. S8). Remarkably, Sub3 had the
highest levels of uPA, Ang-2, HGF, IGFBP-1, OPN, intercellular
adhesion molecule 1 (ICAM-1), and VCAM-1 demonstrating
endothelial activation, damage, and multiorgan failure (Fig. 7d
and Supplementary Fig. S8). Most characteristics for Sub2 was
an extensive secretion of IL-1β, IL-13, GM-CSF, and VEGF
(Fig. 7d and Supplementary Fig. S8), which was already
observed as “late” ICU signature (Fig. 6b). Compared to Sub3,
Sub2 exhibited significantly lower IL-6 and IL-16 levels but
concentrations of IL-18, TNF-α, Ang-2, and OPN were still
elevated compared to Sub1 and UE (Fig. 7d and Supplementary
Fig. S8). However, concentrations of tissue factors like IGFBP-1,
uPA, and HGF were comparable to UE, suggesting less
endothelial dysfunction in Sub2 (Supplementary Fig. S8).
Fig. 5 Systemic inflammation and endothelial injury in COVID-19 patients. Cytokine concentrations in patient sera were measured by
Luminex-based multiplex assay. a Heatmap of cytokine data including 83 plasma proteins from UE (n= 36), ICU (n= 58), and CONV (n= 28).
P value cutoff of 0.01 was used to identify significant differences among the three cohorts. Samples and immune cell subsets were ordered
using to hierarchical clustering. Blue to yellow scale represents the expression values normalized to mean=0, var=1. Missing values are
displayed in white. b Volcano plot visualizing a two-group comparison of plasma protein data from ICU (n= 58) and UE (n= 36). c Correlation
matrix of 83 plasma proteins from ICUs. Spearman correlation was used to calculate correlation coefficients, which were displayed in circles.
The strength of correlation was depicted by circle size. Cytokines were ordered using hierarchical clustering. Red to blue scale indicates the
prevalence of each subset. d Representative cytokine concentrations from UE (n= 36), ICU (n= 58), and CONV (n= 28). Statistical analysis:
Kruskal–Wallis test with Dunn’s multiple comparison test was performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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Fig. 6 Core plasma protein signature of severe COVID-19 consists of 11 inflammatory mediators and endothelial factors. Cytokine
concentrations in patient sera were measured by Luminex-based multiplex assay. a, c Waterfall-plot representing correlation coefficient (r) of
Spearman-correlation analysis between cytokines and disease duration as DASO (a) or SOFA score (c) from ICUs (n= 58). Red columns
represent significant results. Dotted lines represent the minimal Spearman-correlation coefficient (r) required for significant correlation.
b Spearman-correlation analysis between representative cytokines and DASO. d Spearman correlation analysis of representative cytokines
with SOFA score. e Venn diagram displaying significantly positive correlations between plasma proteins and CRP levels, SOFA-, and WHO
score. Triangles represent the last samples from deceased patients. Statistical analysis: Spearman correlation. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001
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In summary, the plasma protein profile of Sub3 implies massive
inflammation, endothelial injury, and impairment of multiple
organs, which is further supported by their high SOFA- and WHO
scores. Patients from Sub2 had longer disease duration and
decreased SOFA- and WHO scores compared to patients from
Sub1 and Sub3. Together with decreased pro-inflammatory
markers and endothelial factors, this indicates a gradual recovery
from COVID-19 for Sub2 patients. Lastly, based on their plasma
protein profile and clinical data, Sub1 patients are considered as
patients at the beginning of a severe COVID-19 progression with
Endothelial dysfunction contributes to severe COVID-19 in combination. . .
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massive inflammation but restricted endothelial damage and
limited impairment of multiple organs.
DISCUSSION
Despite the intense global COVID-19 research, it is still
incompletely understood which molecular mechanisms essen-
tially contribute to severe disease progression and mortality.
High-resolution single-cell-transcriptomic analyses focused
almost exclusively on immune cells and proposed treatment-
relevant signatures.16 Therefore, we aimed at highlighting the
interface between the immune and endothelial systems in order
to define signatures of severe COVID-19 with the potential to
develop novel therapeutic strategies. In our study, we analyzed
the cellular and humoral immune response in ICU and CONV,
including a variety of plasma proteins as they serve as key
mediators of inflammation and endothelial integrity.
In the peripheral blood of ICU, we identified major changes in
the distribution of immune cell populations with a massive
expansion of granulocytes along with a severe lymphopenia.
Even though lymphopenia has been described as hallmark for
severe COVID-19, it remains elusive whether it is caused by tissue
infiltration or destruction of lymphocytes.17 As indicated by the
T-cell signature of CONV, SARS-CoV-2 infection causes a differ-
entiation of naive into effector CD8+ T cells, further supported by
the significant increase of EM CD8+ T cells over time. Thus, the
time-dependent differentiation of several immune cell popula-
tions could explain the high variability among proportions and
numbers of immune cells in ICU. Several changes like the
differentiation to memory T and NK cells persisted also in CONV
arguing for long-term effects that may contribute to Long-COVID.
The immune signature of COVID-19 ICU displayed a highly
activated phenotype, particularly of T and NK cells characterized
by a HLA-DR+CD38+ and CD127− phenotype. Up to 80% of CD8+
T cells in ICU were HLA-DR+CD38+, demonstrating strong T-cell
activation in response to SARS-CoV-2. The appearance of HLA-
DR+CD38+CD8+ T cells has also been described for other viruses
like HIV and Influenza A and was associated with worse outcomes
and impaired T-cell function.18,19 For COVID-19 others have shown
that conversely to their activated phenotype HLA-DR+CD38+CD8+
T cells also expressed exhaustion markers like PD-1 but were still
functional by producing e.g., IFN-γ, granzyme B, and perforin,
suggesting that these cells are not generally functionally impaired
by their PD-1 expression.20,21
Regarding the humoral immunity to SARS-CoV-2, several studies
demonstrated an extraordinary B-cell response with the absence
of germline centers in deceased COVID-19 patients,22 an extensive
class switching to IgG and IgA accompanied by limited somatic
hypermutation,23 as well as TGF-β instructed SARS-CoV-2 unspe-
cific B-cell responses.24 As others have previously shown,8 we
observed a significant expansion of plasmablasts in severe COVID-
19 patients accompanied by IgA and IgG SARS-CoV-2-specific
antibodies. In our study, ICU not only produced high levels of
S- and N-specific antibodies but the majority of these antibodies
also blocked the binding of SARS-CoV-2 RBD to ACE2 in vitro,
indicating the development of functional antibodies. Nevertheless,
these patients developed severe COVID-19 symptoms despite the
presence of blocking antibodies, suggesting that the humoral
immune response alone may be insufficient to prevent critical
disease progressions. As the development of SARS-CoV-2-specific
antibodies in ICU together with the activation and differentiation
of T and NK cells proves that these patients are immunocompe-
tent, other mechanisms are likely to be involved in severe
COVID-19 progression.
In our study, we observed that severely ill COVID-19 patients
were characterized by a massive release of several plasma proteins
indicating endothelial damage and a previously reported COVID-
19-associated cytokine storm.25 We identified seven core plasma
proteins i.e., CXCL8-10, HGF, IL-6, IL-12(p40), and SCGF-β for severe
COVID-19 that were associated with organ failure (SOFA score),
inflammation (CRP level), and lung dysfunction (WHO-score).
Furthermore, elevated levels of IGFBP-1, M-CSF, VCAM-1, and IL-16
correlated with high SOFA- and WHO scores, indicating a
connection of these soluble mediators to multiple organ and
endothelial injuries. Overall, markedly elevated levels of these
plasma proteins depict a highly inflammatory environment as well
as endothelial activation and disruption and therefore are possible
predictors for disease progression and outcome. This assumption
is supported by the finding of Deng et al., who observed increased
concentrations of CXCL8, SCGF-β, and HGF in severe compared to
non-severe SARS-CoV-2-infected patients.26 In particular, they
found HGF discriminating severe vs. non-severe COVID-19 with
84% sensitivity and 98% specificity. Moreover, elevated CXCL9
concentrations could distinguish SARS-CoV-2-associated multi-
system inflammatory syndrome in children from other hyperin-
flammatory syndromes like Kawasaki disease and macrophage
activation syndrome, underlining the potential of CXCL9 as a
predictive marker in COVID-19 disease progression.27
CXCL8-10 as well as IL-6 and IL-12(p40) are highly pro-
inflammatory mediators and elevated in cytokine storm release
syndrome and systemic diseases.25,28 IL-6 serves as a major
orchestrator for systemic inflammation through induction of the
hepatic acute phase response. Furthermore, high circulating levels
of IL-6 as in a COVID-19-associated cytokine storm result in trans-
signaling allowing IL-6 together with sIL-6Rα to activate cells not
expressing the membrane-bound IL-6R, like endothelial cells.25 As a
result of the IL-6-mediated activation, E-cadherin expression is
reduced on endothelial cells leading to vascular hyperpermeability.
Moreover, not only IL-6 but also HGF has been reported to directly
contribute to endothelial disruption and vascular leakage.29 IGFBP-1
and its ligand IGF-1 are known to be elevated in severe lung injuries
like idiopathic pulmonary fibrosis and ARDS.30,31 The fact that
elevated IGFBP-1 levels are associated with hypoxia further
suggests that IGFBP-1 may be a predictor of lung dysfunction
and tissue damage.32 Since soluble VCAM-1 and M-CSF are
additional indicators of endothelial activation and were identified
as hallmark plasma proteins for severe COVID-19,33,34 we propose
that endothelial activation and disruption are major drivers of
severe COVID-19, which has not been demonstrated in parallel to
immune dysregulation before.
Endothelial damage together with elevated levels of pro-
inflammatory cytokines or endothelial factors are not exclusive for
Fig. 7 Endothelial dysregulation as a major contributor to severe COVID-19. Plasma protein concentrations in patient sera were measured by
Luminex-based multiplex assay (a) tSNE analysis of 83 plasma protein data from ICU (n= 58). A variance-value cutoff of 0.146 was used to
identify significant differences within the ICU cohort. Patients were classified into three subgroups. Green: subgroup 1 (sub1), red: subgroup 2
(Sub2), blue: subgroup 3 (Sub3). b Heatmap of 83 plasma protein from ICU (n= 58). A variance cutoff of 0.146 was used to identify significant
differences among the three cohorts. Samples and cytokines were ordered using hierarchical clustering. Blue to yellow scale represents the
expression values normalized to mean = 0, var = 1. Missing values are displayed in white. c Distribution of severity markers SOFA, WHO-score,
CRP levels, PF ratio, and disease duration (DASO) among the three ICU subgroups. dMean values of SOFA-, WHO-score, CRP level, PF ratio, and
DASO for the three ICU subgroups. e Representative cytokine concentrations from ICU subgroups Sub1 (n= 14), Sub2 (n= 16), and Sub3 (n=
28). Statistical analysis: ANOVA test with Turkey multiple comparison test or Kruskal–Wallis with test with Dunn’s multiple comparison test
were performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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COVID-19 but described for other severe virus infections as well.
Dengue virus infection is associated with vascular leakage35 in
addition to elevated levels of HGF and Ang-2, which increased
with disease severity in children suffering from dengue hemor-
rhagic fever36,37. Decreased barrier function and multiorgan
failure38 are characteristic for patients with Ebola infection
together with increased levels of the pro-inflammatory cytokine
and chemokines IL-6 and CXCL8-10.39 Furthermore, enhanced
secretion of uPA and PAI-1 were found in Ebola-infected non-
human primates at an early stage of infection, indicating an
imbalanced coagulation system, as it has been observed for
COVID-19 as well. PAI-1 concentration was also increased in
influenza-infected mice.40 In humans, severe influenza infection is,
like COVID-19, associated with ARDS and elevated levels of pro-
inflammatory cytokines, chemokines, and endothelial factors like
IL-6, TNFα, CXCL8, CXCL10, and HGF.41,42 These results argue for a
crucial role of the endothelial integrity in several severe virus
infections and, thus, indicate that endothelial cells could serve as a
therapeutic target. In line with this, Xu et al. have recently shown
that expression of KLF2, a master transcriptional regulator of
endothelial integrity and homeostasis is downregulated in vitro in
HMVEC-L endothelial cells after treatment with the serum of
severe COVID-19 patients. Interestingly, atorvastatin treatment
reversed these effects in vitro, suggesting statins as a therapeutic
option to control endothelial damage and to retain vascular
homeostasis in severe COVID-19.43
The different plasma protein profiles from ICU suggest a crucial
role of endothelial damage in severe COVID-19 and link the
inflammatory response to endothelial barrier disruption. Focusing
on ICU, unsupervised cluster analyses identified three subgroups
based on their plasma protein profiles and implied a development
from a primarily inflammatory phenotype in Sub1 to additional
endothelial activation and disruption in Sub3 to endothelial
reconstitution and decline of inflammation in Sub2. A highly
inflammatory phenotype with elevated plasma levels of IL-6, IL-12
(p40), IFN-γ, and CXCL10 characterized Sub1 patients without
signs of endothelial damage. In contrast, remarkably high levels of
HGF, Ang-2, OPN, and VCAM-1 in Sub3 represented extended
endothelial activation and disruption in addition to inflammation
also mediated by IL-6, CXCL10, IL-18, and IL-12(p40). Furthermore,
elevated secretion of key regulators of fibrinolysis like uPA and
PAI-1 were unique features of Sub3 and illustrated a dysregulation
of fibrinolysis and coagulation in addition to endothelial damage
and inflammation. Since microthrombotic patterns are well
described for severe COVID-1944 and represent a serious
complication, these results support the assumption of Sub3 as
high-risk patients with systemic inflammation, tissue damage, and
impaired coagulation and therefore poor survival prospects.
Sub2 was characterized by lower levels of pro-inflammatory
cytokines and endothelial factors like IL-6, IL-12(p40), uPA, HGF,
and IGFBP-1, together with decreased SOFA- and WHO scores
suggesting a decline in inflammation and endothelial damage.
Furthermore, Sub2 exhibited the highest levels of the anti-
inflammatory cytokines IL-13 and IL-1β, which correlated with
decreased SOFA- and WHO scores, as well as CRP levels. While IL-
13 was reported to be required for recovery after acute lung injury
by regulating local levels of IL-6, CCL2/MCP-1, and G-CSF, IL-1β is
usually known as a pro-inflammatory cytokine related to
ARDS.45,46 However, other studies propose that IL-1β is involved
in tissue healing and has beneficial effects on endothelial repair
after ARDS.47 In addition, GM-CSF and VEGF are further factors
elevated in Sub2 and significantly increased over time together
with IL-1β and IL-13. Correspondingly, GM-CSF and VEGF also have
been described to essentially contribute to tissue repair and
wound healing.48,49 These observations indicate that elevated
levels of IL-1β, IL-13, GM-CSF, and VEGF after 20 days of symptom
onset are predictors for tissue repair and improved health
condition of severe COVID-19 patients. The observation that
Long-COVID syndrome is characterized by an impairment of
several organ systems including pulmonary, cardiovascular, and
neurophysiological symptoms14 further suggests a continuous
contribution of the endothelial-epithelial barrier to Long-COVID.
Therefore, knowing the mechanisms involved in the establish-
ment and recovery of COVID-19, focusing especially on the
endothelium, may be essential for more precise diagnostics for
Long-COVID and even treatment strategies.
In conclusion, we propose that in severe cases SARS-CoV-2
infection leads to a massive local inflammation developing into a
dysregulated immune activation with cytokine and chemokine
release. The combination of this inflammation with a systemic
endothelial activation can proceed towards capillary leakage and
multiorgan failure. To the best of our knowledge, the present
study shows for the first time that endothelial damage is another
major driver of COVID-19 severity together with substantial
immune dysregulation. Thus, severe and life-threatening condi-
tions of COVID-19 patients are not only characterized by a highly
activated immune phenotype and pro-inflammatory cascades but
also by substantial endothelial injuries, which may explain
multiorgan involvement in severe COVID-19.
Limitations of the study
The limitations of our observational study include the single-
center setting with a rather small and heterogeneous patient
cohort. Furthermore, samples of ICU patients were obtained at
variable time points during disease according to the clinical
procedure in Lower Saxony with MHH serving as a tertiary care
center for severe cases in need of advances life support. Therefore,
a prospective study design with defined time points was not
feasible. Nevertheless, time-dependent alterations could be
identified by combining patient data, a procedure that has been
utilized for many COVID-19 studies. Of course, further studies are
needed to define the therapeutic consequence of our observa-
tions, especially with respect to their impact on long-COVID.
MATERIALS AND METHODS
Study design
In total 25 patients from the intensive care unit (ICU), and 17
convalescent patients were recruited to this observational study
between April and September 2020 at Hannover Medical School
(MHH). The convalescent cohort included former ICU patients. ICU
and CONV had confirmed SARS-CoV-2 infection with the D614G
virus-variant via viral PCR. For some patients, samples were taken at
multiple time points leading to a sample size of 58 for ICU patients
and 28 for convalescent patients. Five patients from ICU died and
were visualized with the last sample obtained before decease. The
clinical severity of COVID-19 was assessed on different parameters
and the time point of disease severity assessment was consistent
with that of blood collection. World Health Organizations (WHO)
eight-point score for COVID-19 trail endpoints was used to classify
the severity of COVID-19 (https://www.who.int/publications/i/item/
covid-19-therapeutic-trial-synopsis) and is based on the require-
ment of non-invasive oxygen supply and mechanical ventilation or
extracorporeal membrane oxygenation. C-reactive protein (CRP)
level was used as inflammation marker. The sepsis-related organ
failure assessment (SOFA) score determines organ function and the
extent of systemic organ failure in patients at ICU. This score is
based on six organ systems, which are the respiratory system,
nervous system, cardiovascular system, liver, kidney, and coagula-
tion. PF ratio represented the individual pulmonary function.
Clinical and demographical characteristics of study participants are
summarized in Supplementary Table 1. Of the 25 ICU patients, 12
received remdesivir, and 6 received Tocilizumab treatment. In
total, 29 unexposed individuals (UE) were enrolled as the control
group, some also at several time points leading to a sample size of
36 for UE.
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Quantification of cells from EDTA blood via TruCount™ analysis
Absolute cell numbers were calculated from whole blood using BD
Trucount™ Tubes (BD Biosciences), following the manufacturer’s
instructions.
Flow cytometry
Flow cytometry analyses were performed as recommended by the
guidelines of leading European scientists of immunology and flow
cytometry communities.50 Whole blood EDTA samples (100 µl)
were incubated with antibodies for surface staining in FACS Buffer
(0,1% NaN3, 2,5% FCS in PBS) at 4 °C for 30 min and followed by
15min erythrocyte lysis using 1× BD Lysing Solution. Cells were
washed with PBS prior to acquisition. All antibodies used for flow
cytometry analyses are listed in Supplementary Table 2. Cells were
acquired and analyzed on a LSRII flow cytometer (BD Biosciences,
USA) using FACS Diva software (v8.0).
Multiplex assays
Luminex-based multiplex assays were used to quantify plasma
proteins and SARS-CoV-2 S- and N-specific antibodies.
Plasma proteins were measured using the Bio-Plex ProTM
Human Assays (Bio-Rad, Hercules, USA): cytokine screening panel
plus ICAM-1 and VCAM-1 (12007283, 171B6009M, 171B6022M),
Cancer Biomarker Panel 1, and Panel 2 (171AC500M, 171AC600M)
and Th17 cytokine Panel 15-Plex (171AA001M) following the
manufacturer’s instructions with thawed plasma and which was
diluted twofold with assay buffer. Standards were reconstituted
and prepared as described in the manufacturer’s instructions.
Standard curves and concentrations were calculated using the
Bio-Plex Manager 6.1 software.
SARS-CoV-2 S- and N-specific antibodies were detected using
the SARS-CoV-2 Antigen Panel 1 IgG, IgM, IgA assay (Millipore
HC19SERM1-85K-04, HC19SERA1-85K-04, HC19SERG1-85K-04) fol-
lowing the manufacturer’s instructions. The assays were per-
formed with thawed plasma, which was diluted 1:200 for ICU and
CONV and 1:100 for UE with assay buffer.
The semi-quantitative readout is given as median fluorescence
intensity (MFI) of >50 beads for each antigen and sample,
acquired by the Bio-Plex 200 machine and the Bio-Plex ManagerTM
Version 6.0 software (Bio-Rad Hercules, USA).
Competitive ELISA
Competitive ELISA was performed to detect blocking antibodies
against SARS-CoV-2 RBD. Plates were coated overnight at 4 °C
with 50 µl/well of recombinant RBD (400 ng/ml). After three times
washing, plates were blocked for 1–2 h at room temperature (RT)
with PBS+ 2% FCS. In total, 0.25 µg/ml biotinylated human ACE2
(Acro Biosystems) were added followed by 50 µl patient plasma
(1:50 dilution). Plates were incubated at RT for 1–2 h and washed
three times afterward. HRP-bound streptavidin (Merck-Millipore)
was added and incubated at RT for 1–2 h, then washed 3–4 times.
TMB substrate (BD Biosciences) was added and the reaction was
stopped with 50 µl H2SO4 (0.5 M). Optical densities were
measured at 450 nm. Efficient blocking was expressed as the
percent neutralization at a 1:50 plasma dilution relative to a UE
control serum.
Statistical analyses
Statistical analyses of the data were performed with GraphPad Prism
v7.0/v9.0 software (GraphPad Software). D’Agostino-Pearson omni-
bus normality test was calculated to assess data distribution.
Parametric tests were performed where data were normally
distributed, otherwise non-parametric tests were used. The statistical
test used in each analysis is indicated in the figure legends.
Correlation analyses were performed using Spearman rank-order
correlation. Results were considered significant if P < 0.05.
Qlucore Omics Explorer (version 3.6, Qlucore) was used to
generate principal component analysis (PCA) plots, heatmaps,
tSNE plots, and volcano plots. Therefore data were normalized to
mean=0 and var=1. Furthermore, cytokine/chemokine data were
log-transformed for Qlucore Omics Explorer analyses. For each
analysis, P value or variance used as a cutoff are indicated in the
figure legends.
For the cytokine correlation matrix, Spearman’s rank-order
correlation coefficient was visualized using the corrplot R package.
Study approval
The study was approved by the Hannover Medical School
Ethics Committee. All patients or participants provided written
informed consent before participation in the study (9001 BO K,
968-2011).
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